Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atai Beckley N.V.ATAI · Entity 72536 | Chief Medical Officer | March 21, 2025 | March 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atai Beckley N.V.
Report date March 21, 2025 · Filed March 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 8,437 |
Reported balance
After 2025-03-21 transaction · row 1
1 source rowRow 1 · 2025-03-21 · Sale · Disposed 11,563 · Balance 8,437 F1: Represents shares sold to satisfy the Reporting Person's tax liability on vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy the Reporting Person's tax liability on vesting of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AtaiBeckley Inc.
Report date September 11, 2026 · Filed September 11, 2026
Section 16 reporting ended · disclosed 2026-09-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Disposition to issuer · Disposed 8,437 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2032-02-11 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-11 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.86 · Expires 2032-10-21 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-11 · Disposition to issuer · Disposed 50,400 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2033-03-14 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-11 · Disposition to issuer · Disposed 28,608 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2034-03-13 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-11 · Disposition to issuer · Disposed 372,701 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-03-03 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-11 · Disposition to issuer · Disposed 673,808 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.76 · Expires 2036-01-30 | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-11 · Disposition to issuer · Disposed 675,000 · Balance 0 F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-11 · Disposition to issuer · Disposed 150,000 · Balance 0 F4: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent.
F2: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding.
F3: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
F4: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerRestricted Stock Units · Derivative | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 8 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). F4 · price: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). F4 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit ("RSU"), subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such RSU immediately prior to the Effective Time multiplied by (2) $6.75 and (B) one CVR for each share subject to such RSU immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 675,000 | Not disclosed Strike: $3.76 | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 7 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 675,000 shares Expires 2036-01-30 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 673,808 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 6 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 673,808 shares Expires 2035-03-03 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 372,701 | Not disclosed Strike: $1.84 | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 5 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 372,701 shares Expires 2034-03-13 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 28,608 | Not disclosed Strike: $1.18 | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 4 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,608 shares Expires 2033-03-14 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 50,400 | Not disclosed Strike: $2.86 | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 3 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,400 shares Expires 2032-10-21 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerStock Option · Derivative | 10,000 | Not disclosed Strike: $5.54 | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · derivative · entry 2 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-02-11 F3 · price: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). F3 · derivative.exercise_date: At the Effective Time, each outstanding stock option of the Company, subject to certain exceptions, was automatically cancelled and converted into the right to receive (A) an amount in cash (without interest and less applicable tax withholdings) equal to the product of (1) the total number of shares subject to such stock option immediately prior to the Effective Time multiplied by (2) the excess of $6.75 over the applicable exercise price per share under such stock option and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| September 11, 2026 Filed Sep 11, 2026 21:44 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Disposition to issuerCommon Stock | 8,437 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-26-036390 · form4.xml · nonDerivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger dated as of July 15, 2026, by and among AtaiBeckley Inc. (the "Company"), Eli Lilly and Company, an Indiana corporation ("Parent"), and Albali Acquisition Corporation, a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"), on September 11, 2026, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. F2 · price: At the effective time of the Merger (the "Effective Time"), each share of the Company's common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, converted into the right to receive (i) $6.75 per share in cash, without interest, plus (ii) one contingent value right per share (each, a "CVR" and collectively, the "CVRs"), representing the right to receive up to an aggregate of $2.50 in cash per CVR upon achievement, if any, of specified clinical and regulatory milestones, less any applicable tax withholding. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 9,528 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001140361-26-026787 · form4.xml · derivative · entry 5 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,608 Underlying: Common Stock · 9,528 shares Expires 2033-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F4 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 33,051 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001140361-26-026787 · form4.xml · derivative · entry 4 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 673,808 Underlying: Common Stock · 33,051 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | SaleCommon Stock | 42,579 | $4.51 | $192,031.29 |
DisclosureSEC source: 0001140361-26-026787 · form4.xml · nonDerivative · entry 3 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,437 F2 · kind: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $4.50 to $4.54. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 9,528 | $1.18 | $11,243.04 |
DisclosureSEC source: 0001140361-26-026787 · form4.xml · nonDerivative · entry 2 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 22:00 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 33,051 | $1.50 | $49,576.50 |
DisclosureSEC source: 0001140361-26-026787 · form4.xml · nonDerivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:32 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 15,299 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001140361-26-016169 · form4.xml · derivative · entry 5 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 372,701 Underlying: Common Stock · 15,299 shares Expires 2034-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on January 1, 2025, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:32 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 27,280 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001140361-26-016169 · form4.xml · derivative · entry 4 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 706,859 Underlying: Common Stock · 27,280 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F2 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:32 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | SaleCommon Stock | 42,579 | $5.00 | $212,895.00 |
DisclosureSEC source: 0001140361-26-016169 · form4.xml · nonDerivative · entry 3 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,437 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:32 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 15,299 | $1.84 | $28,150.16 |
DisclosureSEC source: 0001140361-26-016169 · form4.xml · nonDerivative · entry 2 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 21:32 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 27,280 | $1.50 | $40,920.00 |
DisclosureSEC source: 0001140361-26-016169 · form4.xml · nonDerivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 22:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 23,776 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001140361-26-010932 · form4.xml · derivative · entry 5 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 734,139 Underlying: Common Stock · 23,776 shares Expires 2035-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.52 to $3.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 22:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionStock Option · Derivative | 76,224 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001140361-26-010932 · form4.xml · derivative · entry 4 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,136 Underlying: Common Stock · 76,224 shares Expires 2033-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested as to 25% of the underlying shares on January 1, 2026, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 22:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | SaleCommon Stock | 100,000 | $3.55 | $355,000.00 |
DisclosureSEC source: 0001140361-26-010932 · form4.xml · nonDerivative · entry 3 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,437 F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. F2 · price: The stock option vested as to 25% of the underlying shares on March 14, 2024, with the remaining underlying shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 22:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 23,776 | $1.50 | $35,664.00 |
DisclosureSEC source: 0001140361-26-010932 · form4.xml · nonDerivative · entry 2 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 22:01 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | Exercise / conversionCommon Stock | 76,224 | $1.18 | $89,944.32 |
DisclosureSEC source: 0001140361-26-010932 · form4.xml · nonDerivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 23:54 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-003547 · form4.xml · derivative · entry 2 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. F2 · derivative.exercise_date: Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. F2 · derivative.expiration_date: Each restricted stock unit vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying such award on January 1, 2027 and as to the remaining 75% of the total number of shares on each of the first three anniversaries of January 1, 2027. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 23:54 UTC | AtaiBeckley Inc. ATAI · Entity 4289 | GrantStock Option · Derivative | 675,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001140361-26-003547 · form4.xml · derivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 675,000 Underlying: Common Stock · 675,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: The stock option vests (subject to continued service through each such vesting date) as to 25% of the total number of shares underlying the option on January 1, 2027 and as to the remaining 75% of the total number of shares in 36 substantially equal monthly installments thereafter. Read SEC document |
| March 21, 2025 Filed Mar 25, 2025 01:00 UTC | Atai Beckley N.V. ATAI · Entity 72536 | SaleCommon Shares | 11,563 | $1.35 | $15,610.05 |
DisclosureSEC source: 0001140361-25-010115 · form4.xml · nonDerivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,437 F1 · shares: Represents shares sold to satisfy the Reporting Person's tax liability on vesting of restricted stock units. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 23:29 UTC | Atai Beckley N.V. ATAI · Entity 72536 | Exercise / conversionRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-009514 · form4.xml · derivative · entry 2 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. The restricted stock units vested on March 14, 2025. F1 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. The restricted stock units vested on March 14, 2025. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. The restricted stock units vested on March 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 23:29 UTC | Atai Beckley N.V. ATAI · Entity 72536 | Exercise / conversionCommon Shares | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-25-009514 · form4.xml · nonDerivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. The restricted stock units vested on March 14, 2025. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 14:06 UTC | Atai Beckley N.V. ATAI · Entity 72536 | GrantStock Option · Derivative | 757,915 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001140361-25-007334 · form4.xml · derivative · entry 1 Craig Kevin James · CIK 0002049601 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 757,915 Underlying: Common Shares · 757,915 shares Expires 2035-03-03 F1 · derivative.exercise_date: The stock option shall vest as to 25% on January 1, 2026, with the remaining shares vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.